Thymomas are a rare cancer, but tend to occur in a younger age group, so the risks of secondary malignancy or radiation-associated heart disease need to be considered. My personal opinion is that proton beam therapy needs to be considered for every patient receiving adjuvant radiotherapy for thymoma.
Stereotactic Ablative Radiotherapy (SABR) is a cutting-edge treatment for lung cancer that delivers highly precise radiation therapy to tumours in the lungs. Unlike traditional radiation therapy, which may require numerous sessions, SABR delivers a concentrated dose of radiation in just a few sessions, often as few as one to five.
During SABR, advanced imaging techniques are used to precisely locate the tumour in the lung. The radiation beams are then carefully directed at the tumour from multiple angles, ensuring that the cancer cells receive a high dose of radiation while minimising exposure to surrounding healthy tissue.
SABR is an excellent option for patients with early-stage lung cancer who may not be candidates for surgery due to other medical issues. It offers a non-invasive alternative that can effectively destroy cancer cells while preserving lung function.